Background Lung volume reduction surgery improves survival in selected patients with emphysema, and has generated interest in bronchoscopic approaches that might achieve the same eff ect with less morbidity and mortality. Previous trials with endobronchial valves have yielded modest group benefi ts because when collateral ventilation is present it prevents lobar atelectasis.
Introduction
Despite optimal pharmacological therapy and pulmonary rehabilitation, many patients with chronic obstructive pulmonary disease (COPD) remain very disabled. 1 In carefully selected patients with emphysema, lung volume reduction surgery (LVRS) to resect the worst aff ected areas of lung has improved lung function, exercise capacity health status, and survival. 2 However, this surgical intervention is associated with substantial morbidity, and an early mortality rate of about 5% was reported in the National Emphysema Treatment Trial (NETT) trial, 2 although recent case series have reported lower rates. 3 Nevertheless, there is still reluctance to refer patients for LVRS, 4 and there has been considerable interest in developing novel treatment approaches that can also reduce lung volumes and gas trapping, either more safely than LVRS, or else in patients for whom LVRS is not an option.
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One approach is placing endobronchial valves in the airways supplying the most emphysematous part of the lung using a fi breoptic bronchoscope (ie, bronchoscopic lung volume reduction, BLVR). The valves allow air to leave but not enter the target lobe, causing it to collapse and thus reducing gas trapping. In heterogeneous disease this reduction allows the relatively healthier lung to function better by diverting air to more perfused areas and recruiting previously compressed alveoli. Initial pilot work by our group and others was encouraging, showing that valve placement could reduce dynamic hyperinfl ation, improving exercise capacity in association with improvements in inspiratory capacity and gas transfer. 7, 10 Moreover, follow up of an early cohort showed that all patients in whom radiological atelectasis had occurred (n=5) were alive 6 years after the procedure, whereas eight of the 14 without radiological atelectasis had died 7 raising the possibility that BLVR might, like LVRS, off er a survival advantage in appropriately selected patients.
The VENT study compared unilateral endobronchial valve placement (n=220) with standard medical care (n=101). 5 The protocol did not mask the patients or assessors to the allocation of treatment and no sham procedures were done. The study showed statistically but not clinically signifi cant mean diff erences in forced expiratory volume in 1 s (FEV 1 ; 6·85%) and 6 min walking distance (5·7%) between BLVR and control groups at 6 months. This small eff ect size was considered insuffi cient for Federal and Drug Administration approval. A post hoc analysis identifi ed a subgroup of responders: patients with high heterogeneity and intact interlobar fi ssures who had a much bigger response with a mean 17·9% improvement in FEV 1 seen if fi ssures were intact compared with 2·8% if fi ssures were incomplete. Additionally, patients with the greatest degree of heterogeneity on CT had signifi cantly greater improvement in both FEV 1 and 6 min walking distance.
Based on these data and evidence for a survival benefi t where radiological atelectasis occurred, 7 we did a randomised, double-blind sham-controlled trial of endobronchial valve placement in patients with COPD (the Bronchoscopic Lung Volume Reduction for patients with Heterogeneous emphysema and Intact Fissures study [BeLieVeR-HIFi] ). We hypo thesised that valve placement would lead to a signifi cant improvement in lung function, exercise capacity, and health status.
Methods

Study design and participants
The BeLieVeR-HIFi study was a randomised, parallel group, double-blind sham bronchoscopy controlled trial of unilateral, endobronchial valve placement (Zephyr valves; PulmonX, Redwood City, CA, USA) aimed to achieve lobar occlusion in patients with heterogeneous emphysema and intact interlobar fi ssures. Participants were recruited between March 1, 2012, and Sept 30, 2013.
We enrolled stable outpatients with COPD who met the following criteria: FEV 1 of less than 50% predicted; signifi cant hyperinfl ation (total lung capacity >100% and residual volume >150%); a restricted exercise capacity (6 min walking distance <450 m) and substantial breathlessness (MRC dyspnoea score ≥3). Participants were all ex-smokers and on optimum medical therapy, including combined inhaled corticosteroids, long-acting β2 agonist, and anti-cholinergic agents unless they were intolerant or declined to use them. Patients were identifi ed through a multidisciplinary COPD team meeting including chest physicians, surgeons, and radiologists. For inclusion, a CT scan of their thorax had to show heterogeneous emphysema with a defi ned target lobe with lung destruction and intact adjacent interlobar fi ssures. Scans were reviewed by two radiologists independently and a third adjudicated on any disagreements. Radiologists had to agree that the worst aff ected lobe of the lung had an emphysema score of more than 2 on the NETT study scoring system 2 and that it scored at least 1 point higher than ipsilateral lobes and had more than 90% intact oblique fi ssures visible.
All (n=50)
BLVR (n=25) Control (n=25)
Pack year smoking history 54 (24) 56 (26) 51 (23) Exacerbation rate per year
TLC (% predicted) 137 (14) 132 (12) 143 (15) Residual volume (% predicted) Patients were excluded if they had substantial comorbidity restricting their exercise capacity or prognosis; substantial daily sputum production; or hypoxia (ie, PaO₂ <6·5 Pa breathing air). Lower limits for lung function were not otherwise formally defi ned but patients were excluded if they were considered clinically to be too restricted or frail to undergo bronchoscopy or to tolerate a pneumothorax. The study was approved by the London-Bentham Research Ethics Committee (REC number 11/LO/1608); the sponsor was Imperial College, London. There was a trial steering group and an independent data monitoring committee. All patients provided written informed consent.
Randomisation and masking
We randomly assigned patients (1:1) to either BLVR or control groups using predetermined block randomisation, with a block size of 10, computer-generated by the trial statistician (WB). The allocation was obtained by telephone link from the bronchoscopy suite to the Clinical Trials Unit at the Royal Brompton Hospital once the patient had been sedated. Masking was maintained by having two separate teams: one which undertook the randomised procedures (PLS, ZZ, WHM) and a separate team, masked to study assignment, responsible for recruitment and the assessments (CD, MIP, NSH), as previously used in trials of bronchoscopic therapies for emphysema. 10 Thus, both patients and the researchers assessing outcomes were masked to treatment allocation.
Procedures
The procedures took place within 2 weeks of the baseline assessment visit. Study participants underwent either unilateral lobar endobronchial valve placement aiming to achieve lobar atelectasis (BLVR group), or bronchoscopy and sham valve placement (control group). All procedures were done in the bronchoscopy suite at the Royal Brompton Hospital using moderate sedation with midazolam and alfentanyl. Procedures were done by a single operator (PLS) with an expertise in interventional bronchoscopy who had done more than 50 endobronchial valve procedures before study commencement.
Although target lobe selection was based on CT appearance alone, measurements of collateral ventilation using the Chartis (PulmonX, Redwood City, CA, USA) balloon catheter system were made in all participants so that the accuracy of the two approaches could be compared. 12 Endobronchial valves were placed to occlude segmental bronchi leading to the target lobe (irrespective of the Chartis results). All procedures were unilateral. All patients underwent a chest radiograph after the procedure to check for the presence of a pneumothorax, which was reviewed by the treatment team only. If this was satisfactory they were then discharged home. Patients were counselled and provided with a post-procedure information sheet, irrespective of treatment allocation, giving advice on seeking medical attention in the presence of chest pain or sudden breathlessness, and providing advice for medical staff if the patient presented as an emergency.
Baseline and 3 month follow-up visits were done by an assessment team masked to treatment allocation. Spirometry, gas transfer, and lung volumes assessed by body plethysmography were measured with a CompactLab system (Jaeger, Hoechberg, Germany). 13 Lung function tests were all done after bronchodilator use. Predicted values used were those of the European Coal and Steel Community. 14, 15 Patients underwent endurance cycle ergometry with metabolic measurements at 70% of their maximum workload determined on an initial incremental test. Inspiratory capacity manoeuvres were done to track changes in dynamic hyperinfl ation assessed as end-expiratory lung volume. Patients also completed a 6 min walking test done according to American Thoracic Society guidelines on a 30 m course. 16 Health-related quality of life was assessed using the St George's respiratory questionnaire for COPD (SGRQc) 17 and COPD assessment test (CAT). 18, 19 Target lobe volume change was assessed by a radiologist (DHC) as an explicatory variable and scored as follows: 0, no change; 1, some volume loss (fi ssures shift); 2, segmental atelectasis (band of collapsed lung); 3, complete atelectasis (complete collapse). 
Outcomes
The primary endpoint was the between group diff erence in the percentage change in FEV 1 measured 3 months after the procedure. Secondary endpoints were: change in endurance time (T LIM ) on cycle ergometry at 70% of maximum achieved workload and changes in end expiratory lung volume at isotime; change in 6 min walking distance; and changes in health status (scores on the CAT and SGRQc).
Statistical analysis
Sample size calculation was based on the results in the VENT study subgroup in which complete lobar occlusion was achieved. 5 This group had a mean 20·6% (SD 25·1) improvement in FEV 1 at 6 months compared with a 2·5% (2·5) fall in the control group. We considered an absolute diff erence in response between the two groups of 15% to be clinically signifi cant. An 80% power and a signifi cance level of 0·05 needed 21 patients in each group assuming that the mean change in FEV 1 from baseline in the control group was 0% (2·5) and the mean change in the group receiving BLVR was 15% (25) . 50 patients were recruited to allow a 20% drop-out rate.
Data were entered into an electronic database developed by The Imperial College Clinical Trials Unit using InForm (Oracle, Reading, UK), and analysis was done by the trial statistician (WB) using Stata version 12 and SAS version 9.3 (SAS Institute Inc., Cary, NC, USA). Analysis was on an intention-to-treat basis as pre-specifi ed in a formal statistical analysis plan. Categorical data are presented as percentages and comparisons done using the Pearson χ² test. Normally distributed numeric data are presented as mean with SD or 95% CI. Non-normally distributed numeric data are presented as median (IQR). Because responses were skewed, Mann-Whitney testing was used to test whether the response to BLVR treatment was better than placebo. A post hoc univariate analysis of factors associated with change in cycle endurance time using regression with cluster option (ie, taking into account the paired nature of the data and relaxing the conditions for independence) was done. A p value of less than 0·05 indicated statistical signifi cance. Missing data were imputed using the Markov chain Monte Carlo method, which creates multiple imputations by using simulations from a Bayesian prediction distribution. For responder analyses, minimum clinically important diff erences were pre-specifi ed as a 15% increase for FEV 1 , 350 mL reduction in the residual volume, 20 4 point decrease on the SGRQc scale, 17, 21 2 point decrease on the CAT scale, 19, 22 an increase of 105 s for endurance cycle T LIM , 23 and an increase of 26 m in 6 min walking distance. 24 The trial is registered at controlled-trials.com, ISRCTN04761234. The protocol has been published elsewhere.
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Role of the funding source
The funders of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. The corresponding author had full access to all the data in the study and had fi nal responsibility for the decision to submit for publication.
BLVR
Control p value 
Results
The baseline characteristics of the 50 enrolled patients with COPD are shown in table 1 and more fully in the appendix. BLVR and control groups were generally well matched, but percent predicted residual volume and total lung capacity were higher in the control group. The trial profi le describing patient fl ow through the study is shown in fi gure 1. The median number of valves placed per patient was 3 (range 1-6). There were two deaths in the BLVR group and one control patient was unable to attend for follow-up assessment because of a prolonged pneumothorax; 3 month data were available for 23 patients receiving BLVR and 24 controls. Response to treatment was assessed at 3 months (mean [SD] 93 [12] days; table 2, fi gure 2, and appendix). FEV 1 increased by a mean 24·8% (95% CI 8·0-41·5) from baseline in the BLVR group and 3·9% (0·7-7·1) in controls. However, the response in the BLVR group was heavily skewed so non-parametric tests were used for analysis. Median (IQR) FEV 1 changes at 3 months were 8·77% (2·27-35·85) in the BLVR group and 2·88% (0-8·51) in controls (Mann-Whitney p=0·0326; table 2). The BLVR group also had a signifi cant improvement in 6 min walking distance and T LIM on cycle ergometry (tables 2 and 3). This result was accompanied by signifi cant improvements in lung volumes and gas transfer. CAT and SGRQc scores improved more in the BLVR group but compared with the control group were not statistically signifi cant. Improvement in FEV 1 was not associated with any baseline variable (appendix).
In univariate analysis, improvement in cycle ergometry T LIM was associated with improvements in spirometry, lung volumes, and gas transfer, and reductions in dynamic lung volumes, respiratory rate, and breath lessness during exercise (table 4) . In multivariate analysis, an increase in FEV 1 was retained, together with a fall in isotime respiratory rate and Borg dyspnoea score, as factors associated with improvement in T LIM (r²=0·59, p<0·0001). In the BLVR group, eight patients were scored as having "complete collapse" of the target lobe, fi ve "a band of atelectasis", two "some volume loss", and eight no change.
Four treated patients, despite having fi ssures scored as intact on CT as a criterion for study entry, had collateral ventilation detected by the Chartis system (collateral ventilation positive). Table 5 compares response rates between controls and the whole BLVR group and the BLVR group with collateral ventilation positive patients excluded. Of note, it was not possible to determine collateral ventilation in six (12%) patients with the Chartis system, consistent with a previous study reporting a 7% failure rate. 26 Individual patient responses to treatment are shown in the appendix, including both absolute values and numbers achieving the minimum clinically important diff erences for the various variables measured. These data also show the lobe targeted and whether collateral ventilation was detected by the Chartis system. Two patients in the BLVR group died within 90 days of the procedure (table 6). The fi rst developed a cough and a decision was taken to remove the valves 49 days after they had been placed. At the time of removal, which was diffi cult, he developed a tension pneumothorax with an ongoing signifi cant air leak. He progressed to respiratory 
Univariate analysis of factors associated with change in cycle endurance time using regression with cluster option (ie, taking into account the paired nature of the data and relaxing the conditions for independence). Factors with a p<0·05 in univariate analysis were entered into multiple regression analysis. ΔFEV₁, ΔRR (isotime), and ΔBorg dyspnoea score (isotime) explained 59% of the variance in change in cycle endurance time. failure, dying 17 days later despite intensive care treatment including endotracheal tube intubation and use of arteriovenous extracorporeal CO 2 removal. The second patient died suddenly 3 days after valve placement. He underwent a post mortem; there was no evidence of pneumonia or pneumothorax and a diagnosis of death due to COPD with cor pulmonale was made. One patient in the control group was too unwell to attend for follow-up because of a spontaneous pneumothorax with prolonged air leak with onset 66 days after his sham bronchoscopy. Additionally, two patients in the BLVR group had pneumothoraces which both responded to intercostal tube drainage, one at 3 days and one at 12 days after the procedure. Four patients expectorated a valve before 3 months. These were replaced in three of four individuals before their follow-up visit. The patients were instructed not to inform the assessment team of these additional procedures.
Discussion
Placement of endobronchial valves in patients with severe COPD who have heterogeneous emphysema and intact interlobar fi ssures on CT scan was associated with improvements in lung function and exercise capacity. This prospective, double-blind, randomised, controlled trial is the fi rst study of bronchoscopic treatment to achieve this, through the use of an appropriately stratifi ed approach to target a responder emphysema phenotype (panel). Our data suggest that in appropriately selected patients, endobronchial valve placement results in improvements in lung function which are of a similar order of magnitude to those seen with LVRS. 2,3,27 The improvement in gas transfer is important because this is the lung function variable most strongly associated with survival in people with COPD. 13 Previous trials such as VENT included many patients with collateral ventilation who therefore derived less benefi t, in particular less lobar atelectasis, which is a key determinant of eff ectiveness associated with improved lung function response 5, 8 and survival. 7 Prospectively stratifying in favour of patients with heterogeneous disease and radiologically intact fi ssures substantially increased the response rate.
The success rate of valve placement was higher than in previous studies because only patients with intact interlobar fi ssures on CT were included; however, there were cases of positive collateral ventilation when assessed using the Chartis system. These cases were associated with no benefi t from treatment raising the possibility of an additive role in improving patient selection. The Chartis system adds cost and time to procedures and its use cannot necessarily be recommended based on the present data. Furthermore, satisfactory Chartis measurements were not always possible for technical reasons (about 10%), a fi nding consistent with previous studies. 26 We acknowledge that the positive and negative predictive power of collateral ventilation measured with the Chartis system will vary depending on the CT criteria and method of fi ssure analysis used in the initial selection strategy because this will aff ect the pre-test probability of collateral ventilation. The ideal strategy for selecting patients in whom lobar exclusion can be achieved needs to be defi ned and will remain unclear as refi nements in technology and CT scoring of fi ssure integrity evolve.
A key issue is the safety of this treatment approach. Spontaneous pneumothorax can occur when valve placement leads to a change in the conformation of the lung and can be a marker of eff ective lobar occlusion. Therefore, as patient selection improves an increase in the pneumothorax rate is inevitable. In the present study pneumothorax occurred in two treated patients (8%) and in one control patient (4%). The management of pneumothorax in this context is conventional, usually with intercostal tube drainage. However, it is important that patients are selected who are considered likely to be able to withstand the associated acute lung function impairment a pneumothorax will cause. In part, bronchoscopic treatment for emphysema has been developed for people considered to be too disabled to withstand LVRS, but caution is needed given the pneumothorax risk. There were two deaths in the BLVR group. One occurred as a complication of valve removal, which was diffi cult. Therefore, if valves need to be removed this should be done with limited force and if the valve cannot be removed easily a more controlled approach via rigid bronchoscopy should be considered. A rigid bronchoscopy approach might also be appropriate where there is signifi cant granulation tissue or where the valve is at an acute angle. Because rigid bronchoscopy tends to be done by surgeons rather than physicians, this emphasises the importance of close liaison with thoracic surgery in the approach to the management of these patients. A strength of the study was the masking of patients and assessors. The presence of a sham bronchoscopy meant that a more confi dent estimate could be made of changes in health status that have often been large in unmasked studies, even in the absence of signifi cant changes in lung function. 28 The assessment of collateral ventilation in all participants using the Chartis system meant that control patients also underwent a procedure, which reinforced masking. Although patients in whom a pneumothorax occurred or who expectorated a valve were unmasked, valves are diffi cult to visualise on chest radiographs and this maintained masking of physicians and patients alike if they underwent investigations for a clinical deterioration in the absence of a pneumothorax.
The study was undertaken at a single centre with experience in bronchoscopic procedures and in selecting patients for lung volume reduction. Therefore, it shows the results that are possible. However, for these results to be generalisable, it will require the establishment of a similar clinical infrastructure, and as with any new technique, there is likely to be a learning curve as it is implemented.
In some patients, ideal positioning of the valves is not possible due to patient anatomy (eg, insuffi cient length of bronchus to place the valve adequately leading to early expectoration, or diffi cult access to a particular segment), which might aff ect the eff ectiveness of valves as a treatment strategy. The present study was not suffi ciently large for this to be an issue but we recommend in future studies that a bronchoscopic assessment of the technical feasibility of valve placement be included in the protocol. It remains the case that LVRS is an eff ective treatment in upper lobe predominant bullous emphysema regardless of fi ssure integrity.
Further work is needed to establish how this technique should best be deployed relative to LVRS 2,3 and other developing techniques, such as lung volume reduction coils 9 and bronchoscopic thermal vapour ablation. 29 Most importantly, there is a considerable overlap between the indications for BLVR and LVRS, and thus a stepwise approach with bronchoscopic techniques considered at an earlier stage to defer, prevent, or act as a bridge to LVRS could be appropriate. Alternatively, LVRS might be the defi nitive treatment that should be off ered earlier.
Prospective trials comparing LVRS and valve placement will be needed to clarify this.
